Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11639599 | 0.87 | L3MBTL1 (0.56) | L3MBTL1POLBATMCACNA1BTSHR | |
| SCHEMBL31539990 | 0.85 | TSHR (0.53) | L3MBTL1POLBATMCACNA1BTSHR | |
| SCHEMBL12691945 | 0.85 | TSHR (0.53) | L3MBTL1POLBATMCACNA1BTSHR | |
| SCHEMBL1644001 | 0.79 | CHRM2 (0.64) | L3MBTL1GAARAB9AALDH1A1CHRM2 | |
| SCHEMBL9289413 | 0.78 | GAA (0.53) | L3MBTL1POLBGAALMNAALDH1A1 | |
| SCHEMBL7570776 | 0.78 | MTNR1A (0.49) | L3MBTL1CACNA1BMTNR1BRAB9AALDH1A1 | |
| SCHEMBL11215406 | 0.76 | CACNA1B (0.63) | L3MBTL1CACNA1BTSHRADRA2CGAA | |
| SCHEMBL18826798 | 0.76 | L3MBTL1 (0.55) | L3MBTL1POLBATMCACNA1BTSHR | |
| SCHEMBL11512622 | 0.76 | IDO1 (0.55) | ADRA2CCHRM2MAPT | |
| SCHEMBL9402442 | 0.76 | KDM4E (0.47) | L3MBTL1POLBATMTSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458368-B1 | USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF COGNITIVE FAILURE | LILLY CO ELI (US) | 2007-11-21 | — | — | EP | disclosed |
| CN-1713900-A | Use of norepinephrine reuptake inhibitors for the treatment of cognitive disorders | LILLY CO ELI (US) | 2005-12-28 | — | — | CN | disclosed |
| US-20050009925-A1 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | BYMASTER FRANKLIN PORTER (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1458368-A1 | USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003049724-A1 | USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009925-A1 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | SLC6A2, PNMT, SLC6A3 | L3MBTL1 1409/4885POLB 3046/4885ATM 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.